Penetrance Analysis of the <i>PALB2</i> c.1592delT Founder Mutation

Abstract

Our results suggest that it may be appropriate to offer PALB2 c.1592delT mutation testing to Finnish women with breast cancer, especially those with an early age at onset or a family history of breast or related cancers, and to offer carriers the option of participation in extended disease surveillance programs.